143 results
Page 7 of 8
CORRESP
7sd2wnh49 sowes8mn7
13 Mar 09
Correspondence with SEC
12:00am
8-K
EX-99.1
dy2dlyqniao
27 Feb 09
Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
12:00am
CORRESP
pxd8oc59
5 Feb 09
Correspondence with SEC
12:00am
8-K
EX-99.1
wgty 9dgybq7cpslqby
5 Feb 09
Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
12:00am
8-K
EX-99.1
7phj70x66zqtnwgdd
3 Nov 08
Amicus Therapeutics Announces Third Quarter 2008 Financial Results
12:00am
8-K
EX-99.1
t4npsn xymvszpdhnu
15 Sep 08
Entry into a Material Definitive Agreement
12:00am
8-K
EX-99.1
2dej1r8 nye
7 Aug 08
Amicus Therapeutics Announces Second Quarter 2008 Financial Results
12:00am
8-K
EX-99.1
g0n08c4 eehvl1h12
13 May 08
Amicus Therapeutics Announces First Quarter 2008 Financial Results
12:00am
8-K
EX-99.1
0djia8z
29 Jan 08
Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
12:00am
8-K
EX-99.1
1c23na9bm2xmhz308y
13 Nov 07
Amicus Therapeutics and Shire plc enter into $440 million ex-US Licensing Agreement to Develop and Commercialize AmigalTM, PliceraTMand AT2220
12:00am
8-K
EX-99.1
ejtpemc4p xq
31 Oct 07
Amicus Therapeutics Announces Third Quarter 2007 Financial Results
12:00am
8-K
EX-99.1
npo1i sm2hpu5g8
7 Aug 07
Amicus Therapeutics Announces Second Quarter 2007 Financial Results
12:00am
424B4
hcy9nuylxkmh
31 May 07
Prospectus supplement with pricing info
12:00am